Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
157 hedge funds and large institutions have $437M invested in Mersana Therapeutics in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 44 reducing their positions, and 20 closing their positions.
1,243% more call options, than puts
Call options by funds: $8.89M | Put options by funds: $662K
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
16% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 44
3% more funds holding
Funds holding: 152 → 157 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.11% less ownership
Funds ownership: 4.06% → 3.95% (-0.11%)
26% less capital invested
Capital invested by funds: $593M → $437M (-$156M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$19.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$10.6M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$8.38M |
| 4 |
5VM
5AM Venture Management
San Francisco,
California
|
+$6.65M |
| 5 |
Goldman Sachs
New York
|
+$5.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13.5M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$3.37M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$3.07M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.97M |
MRSN Hedge Fund Activity: Q1 2023 in Review
157 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q1 2023, worth a combined $437M — down 26% from $593M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new MRSN positions and 20 closed out — a net gain of 6 holders — while 51 added to existing stakes and 44 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $19.3M. The largest seller was Millennium Management, cutting an estimated $13.5M.
- 157 institutional investors held Mersana Therapeutics (MRSN) as of Q1 2023, up from 152 in Q4 2022.
- Funds reported $437M of Mersana Therapeutics stock for Q1 2023, down 26% quarter-over-quarter.
- 26 funds opened new Mersana Therapeutics positions in Q1 2023 and 20 closed out, a net change of +6 holders.
- The largest Mersana Therapeutics buyer in Q1 2023 was Avidity Partners Management, an estimated $19.3M added.
- The largest Mersana Therapeutics seller in Q1 2023 was Millennium Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q1 2023.